The product should be used prophylactically, therapeutically or as supportive treatment.Therapeutically and prophylactically - in children and adults according to diagram A: in the case of long-lasting, chronic and recurrent inflammation of the upper and lower respiratory tract, including sinusitis and nasopharyngeal sinusitis, recurrent laryngitis, tracheitis and bronchitis (recommended prophylactic treatment in the remission period) and middle ear.Therapeutically - in adults according to scheme B: in cases of chronic and recurrent neuralgia: trigeminal and occipital nerve, sciatica, plexus inflammation and intercostal neuralgia.Adjunctive therapy - in adults according to Scheme C: in cases of chronic inflammation of the bladder, vagina, appendages and endometrium.
Composition:
Polyvaccinum submite. 1 ml of the vaccine contains inactivated bacteria in the number of 5 million cellsStaphylococcus aureus, 5 millionStaphylococcus epidermidis, 1 millionStreptococcus salivarius, 1 millionStreptococcus pneumoniae, 1 millionStreptococcus pyogenes, 2 millionEscherichia coli, 1 millionKlebsiella pneumoniae, 1 millionHaemophilus influenzae, 2 millionCorynebacterium pseudodiphtheriticum, 1 millionMoraxella catarrhalis. Polyvaccinum mite. 1 ml of the vaccine contains inactivated bacteria in the amount of 50 million cellsStaphylococcus aureus50 millionStaphylococcus epidermidis, 10 millionStreptococcus salivarius, 10 millionStreptococcus pneumoniae, 10 millionStreptococcus pyogenes20 millionEscherichia coli, 10 millionKlebsiella pneumoniae, 10 millionHaemophilus influenzae, 20 millionCorynebacterium pseudodiphtheriticum, 10 millionMoraxella catarrhalis. Polyvaccinum forte. 1 ml of the vaccine contains inactivated bacteria in the number of cells: 500 millionStaphylococcus aureus, 500 millionStaphylococcus epidermidis, 100 millionStreptococcus salivarius, 100 millionStreptococcus pneumoniae, 100 millionStreptococcus pyogenes, 200 millionEscherichia coli, 100 millionKlebsiella pneumoniae, 100 millionHaemophilus influenzae, 200 millionCorynebacterium pseudodiphtheriticum, 100 millionMoraxella catarrhalis.
Action:
Non-specific bacterial vaccine. The active substances of vaccines are suspensions of bacteria killed by heating, most often causing infections or causing complications of inflammatory states of non-bacterial origin. The preparation is used prophylactically and therapeutically. Vaccines work by immunostimulatory enhancing the general, non-specific immunity of the immune system leading to the strengthening of the defense system against infection. At the same time, they induce a specific resistance to bacteria whose antigens are contained in vaccines.
Contraindications:
Hypersensitivity to the active substance or any of the excipients. Infectious diseases. acute inflammation. Diseases of the kidneys and liver. Failure of circulation. Pregnancy and breastfeeding. Children under 2 years. Systemic diseases. The use of immunosuppressive drugs.
Precautions:
Vaccination should be preceded by a thorough medical history (with particular reference to previous vaccinations and side effects that could have been caused) and a medical examination. It should be possible to immediately treat the patient in the event of anaphylactic shock. In patients undergoing immunosuppressive therapy, the response to the vaccine may be reduced - in this case, it is recommended to postpone the vaccination until the end of therapy. The vaccine may be administered during the course of the infection if the treatment has started before the infection develops. Do not give intravascularly. After vaccination the patient should remain under the doctor's supervision for 30 minutes.
Pregnancy and lactation:
Do not use during pregnancy and breastfeeding.
Side effects:
The following may occur: headache, nausea, redness, swelling, pain at the injection site, transient, 6-8 h fever (up to 38 ° C), malaise, general weakness, local inflammation (exacerbation). These symptoms usually disappear after 24 h. If longer side effects persist (headache, nausea, general weakness), the time between injections should be increased and the dose of the vaccine should be reduced (return to a concentration of 10 times less bacteria and / or reduced vaccine dose volume).
Dosage:
Intramuscularly or subcutaneously. An arm muscle is recommended as an injection site.Therapeutically and prophylactically - scheme A. Injections given in intervals of 3-5 days.Adults: injection of 1,2 and 3 - Polyvaccinum submite 1 ml; injection of 4 and 5 - Polyvaccinum mite 0.5 ml; injection of 6, 7 and 8 - Polyvaccinum mite 1 ml; injection of 9 and 10 - Polyvaccinum forte 0.3 ml; injection of 11 and 12 - Polyvaccinum forte 0.5 ml; injection of 13 and 14 - Polyvaccinum forte 1 ml.Children up to 14 years old: injection of 1,2 and 3 - Polyvaccinum submite 0.5 ml; injection of 4 and 5 - Polyvaccinum submite 1 ml; injection of 6, 7 and 8 - Polyvaccinum mite 0.3 ml; injection 9 and 10 - Polyvaccinum mite 0.5 ml; injection of 11 and 12 - Polyvaccinum forte 0.2 ml; injection of 13 and 14 - Polyvaccinum forte 0.5 ml. Dose 14 can be repeated at intervals of 2-4 weeks for a period of 2-3 months. The above full vaccination course should be repeated twice a year in spring and autumn for at least 2 years.Therapeutically - scheme B. Injections given in intervals of 3-4 days.Adults: injection 1 and 2 - Polyvaccinum submite 0.5 ml; injection of 3, 4, 5 and 6 - Polyvaccinum submite 1 ml; injection of 7, 8, 9, 10, 11 and 12 - Polyvaccinum mite 0.5 ml; injection of 13, 14, 15, 16, 17 and 18 - Polyvaccinum mite 1 ml.Supportive therapy - scheme C. Injections given in intervals of 2-4 days.Adults: injection of 1, 2 and 3 - Polyvaccinum submite 1 ml; injection of 4, 5 and 6 - Polyvaccinum mite 0.5 ml; injection 7 and 8 - Polyvaccinum mite 1 ml; injection of 9 and 10 - Polyvaccinum forte 0.5 ml; injection of 11 and 12 - Polyvaccinum forte 1 ml. There are no data available on the use of Polyvaccinum submite, mite and forte in accordance with Scheme B and C in children and adolescents.